On July 26, 2012, Regeneron Pharmaceuticals, Inc. (REGN) announced results for the second quarter ending June 30, 2012. The company posted a 182.2% year-to-year increase on total revenues of (Dollar) 304.3 million in Q2 2012, beating The Street's estimate of (Dollar) 257 million. Regeneron continues to be elated from the successful launch of its neovascular (wet) aged-related macular degeneration (wet AMD) drug Eylea (afilibercept) which was approved back in November 2011. Domestic sales of ...For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
No comments:
Post a Comment